Baricitinib is an oral medication that inhibits Janus kinases (JAK1 and JAK2), enzymes involved in the signaling of inflammatory cytokines, making it effective in treating autoimmune conditions like rheumatoid arthritis. It was discovered by researchers at Eli Lilly and Company in the early 2000s as part of a focused effort to develop targeted therapies for inflammatory diseases. Baricitinib was approved in 2017 by the European Medicines Agency and the US FDA for moderate to severe rheumatoid arthritis in patients who had inadequate responses to conventional therapies. Over time, its therapeutic applications expanded, including emergency use authorization during the COVID-19 pandemic to reduce inflammation in hospitalized patients. Its development marked a significant advancement in precision medicine, highlighting the potential of JAK inhibitors to modulate specific immune pathways while minimizing systemic immunosuppression.
